Rznomics Joins Lilly Gateway Labs in San Diego to Advance RNA-Based Gene Therapies

Rznomics Inc., a South Korean clinical-stage biopharmaceutical company focused on RNA-based gene therapies, has joined Lilly Gateway Labs in San Diego, California.

The move gives Rznomics access to a biotechnology innovation environment where companies can use wet lab facilities and interact with scientists and executives from Eli Lilly and Company.

For Rznomics, the partnership is aimed at speeding up research, expanding its development capabilities in the United States, and building stronger connections with the global biotechnology industry.

What Is Lilly Gateway Labs?

Lilly Gateway Labs is an innovation hub created to support biotechnology companies working on new medicines and technologies.

Companies participating in the program can gain access to laboratory facilities and opportunities to engage with Lilly researchers and executives. The goal is to give biotech companies additional resources as they move their research programs toward clinical development.

Lilly Gateway Labs is part of Lilly Catalyze360, a broader platform designed to support biotechnology innovation.

Catalyze360 brings together several initiatives, including Lilly Ventures, Lilly ExploR&D and Lilly TuneLab. These programs provide different forms of support, including access to strategic capital, laboratory space, technology, research capabilities and development expertise.

Rznomics Plans to Expand Candidate Discovery

Rznomics plans to use its presence at Lilly Gateway Labs to accelerate the discovery and development of new therapeutic candidates.

The company has a target gene database bank containing more than 200 disease targets. According to Rznomics, the platform could be used to identify and advance additional RNA-based therapeutic programs across different diseases.

The company is also planning to use its US presence to support longer-term clinical development activities.

This includes building global clinical infrastructure for its lead programs, developing strategic partnerships and recruiting experienced R&D researchers in the United States.

Focus on the Company's RNA Technology

Rznomics is developing RNA-based gene therapies using its proprietary trans-splicing ribozyme platform.

The technology is designed to enable precise RNA editing. In simple terms, the platform is intended to modify RNA in a targeted way, creating opportunities to develop therapies for different diseases.

The company believes the technology can be applied across multiple therapeutic areas.

Rznomics is currently a clinical-stage company, meaning its technology and drug candidates are progressing through human clinical development rather than remaining only at the laboratory research stage.

Why San Diego Matters for Rznomics

San Diego is one of the major biotechnology and life sciences centers in the United States.

By establishing a presence within Lilly Gateway Labs, Rznomics expects to become more closely connected with the US biotechnology ecosystem.

The company plans to use this opportunity to work with researchers and industry participants while building relationships that could support future drug development programs.

For Rznomics, the move is also part of a broader effort to strengthen its international presence.

Building Global Clinical Infrastructure

Rznomics is not limiting its plans to laboratory research.

The company said it intends to establish global clinical infrastructure for its lead pipelines. This could support future clinical trials and development activities as its drug candidates move through later stages of development.

Having a stronger presence in the United States can also help the company build relationships with researchers, clinical organizations and potential development partners.

The company is also looking to recruit top-tier R&D researchers in the US as part of its expansion strategy.

Rznomics CEO Comments on the Move

Seong-Wook Lee, CEO of Rznomics, described the company's entry into Lilly Gateway Labs as an important milestone for its RNA platform.

Lee said the company plans to advance the development and commercialization of its RNA therapeutics by working more actively with the global biotechnology ecosystem.

The company expects its presence in San Diego to support both its research activities and broader international development plans.

Rznomics' RNA-Based Gene Therapy Approach

RNA-based therapies have become an important area of research in the biopharmaceutical industry.

Instead of directly changing DNA, RNA-based approaches can be used to influence how genetic information is processed or expressed inside cells.

Rznomics is taking a specific approach through its trans-splicing ribozyme technology.

The company's platform is designed to perform targeted RNA editing and can potentially be applied to multiple disease targets.

With more than 200 targets in its database, Rznomics is looking to build a broader pipeline around this technology rather than developing a single drug for one disease.

A New Stage for Rznomics' US Expansion

Joining Lilly Gateway Labs gives Rznomics a physical base in San Diego while the company works to expand its research and development activities outside South Korea.

The company plans to use the platform to accelerate candidate discovery, strengthen its clinical development infrastructure, expand global partnerships and bring additional research talent into its US operations.

Rznomics is now positioned to continue developing its RNA-based therapeutic pipeline while increasing its participation in the international biotechnology ecosystem.

About Rznomics

Rznomics Inc. is a clinical-stage biopharmaceutical company headquartered in South Korea.

The company focuses on developing RNA-based gene therapies using its proprietary trans-splicing ribozyme platform.

Its technology is designed for precise RNA editing and is being explored for applications across multiple disease areas.

Through its expansion into Lilly Gateway Labs in San Diego, Rznomics plans to strengthen its research capabilities, expand its global development network and advance its pipeline of RNA-based therapeutic candidates.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!